Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma
Open Access
- 1 January 2006
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 12 (16), 2563-2568
- https://doi.org/10.3748/wjg.v12.i16.2563
Abstract
AIM: To evaluate the immunohistochemical localization of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) on tumor tissue specimens from patients with hepatocellular carcinoma (HCC) and the serum levels of IL-6 and sIL-6R in a group of patients with HCC as well as liver cirrhosis (LC) in a group of patients with LC alone and in a control group. METHODS: Three groups of subjects were studied: group I (n = 83) suffering from HCC and LC, group II (n = 72) suffering from LC alone and group III (n = 42) as healthy controls. All patients had hepatitis C virus infection. Serum IL-6 and IL-6R levels were determined using a commercially available ELISA kit. Immunohistochemistry was performed using the streptavidin-biotin complex and rabbit polyclonal antibodies against IL-6 and IL-6R. RESULTS: Immunohistochemistry analysis showed a medium to strong cytoplasmic and membrane reactivity for IL-6 and IL-6R respectively, in at least 40% of cases of HCC, whereas liver cirrhosis patients and controls were negative for IL-6 or showed a very mild and focal dot-like cytoplasmic reaction for IL-6R. Serum IL-6 levels in HCC group were significantly higher than those in LC and control groups (P < 0.0001). There was no significant difference in sIL-6R concentrations among 3 groups. When the patients with HCC were divided into groups according to Okuda’s classification, a significant serum increase of IL-6 and sIL-6R level was observed from stage I to stage III (P < 0.02, P < 0.0005). When HCC and LC patients were divided into 3 classes of cirrhosis severity according to Child-Pugh, values in HCC patients were significantly higher than those in LC patients for each corresponding class (P < 0.01). CONCLUSION: IL-6 serum levels in HCC patients are higher than those in LC patients and controls, suggesting an increased production of this cytokine by neoplastic cells. sIL-6R values are similar in all groups, increasing only in stage III HCC patients. These data suggest that they have a closer relationship with the neoplastic mass rather than with the residual functioning hepatic mass.Keywords
This publication has 37 references indexed in Scilit:
- Circulating IL‐6 and sIL‐6R in Patients with Hepatocellular CarcinomaAnnals of the New York Academy of Sciences, 2002
- Circulating IL‐6‐type cytokines and sIL‐6R in patients with multiple myelomaBritish Journal of Haematology, 1999
- Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liverThe EMBO Journal, 1998
- Marked Elevation of Serum Interleukin-6 in Patients With CholangiocarcinomaAnnals of Surgery, 1998
- Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.The Journal of cell biology, 1993
- Elevated serum interleukin-6 levels in patients with acute hepatitisJournal of Clinical Immunology, 1992
- Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.JCI Insight, 1991
- Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1991
- Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.JCI Insight, 1989
- Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomasFEBS Letters, 1989